Morgan Stanley
AVBP icon

Morgan Stanley’s ArriVent BioPharma AVBP Stock Holding History

Morgan Stanley’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.6M Buy
189,910
+61,364
+48% +$1.81M ﹤0.01% 4037
2026
Q1 		$2.97M Buy
128,546
+30,956
+32% +$699K ﹤0.01% 4477
2025
Q4 		$1.96M Sell
97,590
-294,432
-75% -$6.13M ﹤0.01% 4823
2025
Q3 		$7.23M Buy
392,022
+290,668
+287% +$5.71M ﹤0.01% 3842
2025
Q2 		$2.21M Sell
101,354
-20,584
-17% -$427K ﹤0.01% 4637
2025
Q1 		$2.25M Sell
121,938
-26,646
-18% -$652K ﹤0.01% 4524
2024
Q4 		$3.96M Sell
148,584
-19,150
-11% -$550K ﹤0.01% 4190
2024
Q3 		$3.94M Buy
167,734
+126,350
+305% +$2.87M ﹤0.01% 4143
2024
Q2 		$768K Buy
41,384
+20,243
+96% +$361K ﹤0.01% 5111
2024
Q1 		$378K Buy
+21,141
New +$426K ﹤0.01% 5434

Other funds holding AVBP

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $983M AUM 26.53% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley's AVBP Position: Q2 2026 in Review

Morgan Stanley increased its ArriVent BioPharma (AVBP) stake by 48% in Q2 2026, buying an estimated $1.81M and bringing the position to 189,910 shares worth $6.6M. The position accounts for ﹤0.01% of the portfolio, ranked #4037.

Morgan Stanley first reported a position in AVBP in Q1 2024 and has held it in 10 quarters since. The position peaked at $7.23M in Q3 2025. 157 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

  • Morgan Stanley held 189,910 shares of ArriVent BioPharma worth $6.6M as of Q2 2026.
  • Morgan Stanley bought 61,364 ArriVent BioPharma shares in Q2 2026, an estimated $1.81M.
  • ArriVent BioPharma made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4037 holding.
  • Morgan Stanley first reported a position in ArriVent BioPharma in Q1 2024 and has held it in 10 quarters since.
  • Morgan Stanley's ArriVent BioPharma position peaked at $7.23M in Q3 2025.
  • 157 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.